ReviewWorld journal of gastroenterology2004
Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up.
Review in World journal of gastroenterology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 60 citations in OpenAlex.
- Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma.World journal of gastroenterology · 2005Trial
- Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study.Frontiers in oncology · 2024Article
- MRI monitoring of combined therapy with transcatheter arterial delivery of NK cells and systemic administration of sorafenib for the treatment of HCC.American journal of cancer research · 2024Article
- Updates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI.Journal of magnetic resonance imaging : JMRI · 2023Review
- Correlation between magnetic resonance images of peritumor margin enhancement and prognosis in hepatocellular carcinoma after drug-eluting bead transcatheter arterial chemoembolization.Frontiers in oncology · 2023Article
- Current Imaging Diagnosis of Hepatocellular Carcinoma.Cancers · 2022Review
- Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.Abdominal radiology (New York) · 2021Review
- LI-RADS treatment response assessment of combination locoregional therapy for HCC.Abdominal radiology (New York) · 2021Review
- Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions.World journal of hepatology · 2020Review
- Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review.Insights into imaging · 2019Review
- Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis.La Radiologia medica · 2015Article
- New approaches for precise response evaluation in hepatocellular carcinoma.World journal of gastroenterology · 2014Review
- Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring.Cancer imaging : the official publication of the International Cancer Imaging Society · 2013Review
- Imaging and Imaging-Guided Interventions in the Diagnosis and Management of Hepatocellular Carcinoma (HCC)-Review of Evidence.Iranian journal of radiology : a quarterly journal published by the Iranian Radiological Society · 2012Article
- Hepatocellular carcinoma treated with transarterial chemoembolization: dynamic perfusion-CT in the assessment of residual tumor.World journal of gastroenterology · 2010Article
- Metabolic restaging of hepatocellular carcinoma using whole-body F-FDG PET/CT.World journal of hepatology · 2009Article
- Combined therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation for small hepatocellular carcinoma.World journal of gastroenterology · 2009Article
- Power Doppler ultrasonography with time-signal intensity curves in monitoring hepatocellular carcinoma and liver metastases after intralesional therapy.La Radiologia medica · 2009Article
- Post-treatment imaging of liver tumours.Cancer imaging : the official publication of the International Cancer Imaging Society · 2007Review
- Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies.World journal of gastroenterology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past decade, a variety of interventional procedures have been employed for local control of hepatocellular carcinoma (HCC). These include transcather arterial chemoembolization (TACE) and several tumour ablation techniques, such as percutaneous ethanol injection (PEI), radio-frequency ablation (RFA), or percutaneous microwave coagulation therapy (PMC), laser-induced interstitial thermotherapy (LITT), etc. For a definite assessment of the therapeutic efficacy of interventional procedures, histological examination using percutaneous needle biopsy may be the most definite assessment of the therapeutic efficacy of interventional therapy, however, it is invasive and the specimen retrieved does not always represent the entire lesion owing to sampling errors. Therefore, computed tomography (CT) and magnetic resonance imaging (MRI) play a crucial role in follow-up of HCC treated by interventional procedures, by which the local treatment efficacy, recurrent disease and some of therapy-induced complications are evaluated. Contrast enhanced axial imaging (CT or MR imaging) may be the most sensitive test for assessing the therapeutic efficacy. The goal of the review was to describe the value of CT and MRI in the evaluation of interventional treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.